FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785891500> ?p ?o ?g. }

• W2785891500 endingPage "3460" @default.
• W2785891500 startingPage "3460" @default.
• W2785891500 abstract "Abstract Systematic review of infectious events in prospective trials of Ibrutinib Ibrutinib is an oral small molecule inhibitor of Bruton tyrosine kinase (BTK). It is efficacious in the treatment of multiple B cell lineage disorders including chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom macroglobulinemia. Use is expanding with ongoing clinical trials in solid tumor oncology as well as recent FDA approval for the treatment of chronic graft versus host disease (GVHD). As experience with newer targeted agents increases we are developing better appreciation and recognition of sometimes unanticipated toxicities. While the most common side effects with ibrutinib are rash and diarrhea, signals of concern have been seen with adverse effects related to hemorrhage, pneumonitis and recent attention to cardiac arrhythmias. Based on our own institutional experience, we updated a preliminary systematic review of infectious events in prospective trials of ibrutinib in the treatment of hematologic disorders. We reviewed the published literature and major conference abstracts using PubMed, Google Scholar and HemOnc.org. Publications through July 1, 2017 were included in the evaluation. All prospective trials of ibrutinib for the treatment of hematologic malignancies were included in the analysis. Those trials involving solid oncologic tumors, GVHD or following allogeneic stem cell transplant were excluded. Infectious events included pneumonia, sepsis, genitourinary and respiratory tract infections, sinusitis, cellulitis, infectious colitis or febrile neutropenia. Neutropenia without fever as well as inflammatory conditions (e.g., pneumonitis) without mention of infection were not included. Pneumonia was separately annotated and included bacterial, fungal, viral or other atypical causes if identified. Events were grouped by grade according to the Common Terminology Criteria for Adverse Events, version 4.03. In multi-arm trials only the ibrutinib-containing arms were included in the analysis and we generally restricted this on an intention-to-treat basis. From the updated literature review, 929 publications from PubMed, 772 from meeting abstracts and more than 11,000 from Google Scholar were identified. 33 peer reviewed publications and 106 abstracts reporting on 61 trials including more than 2300 patients were identified. Infectious adverse events of any grade were identified in over half of the patients for which data was available. Additionally, pneumonia accounted for half of the grade 3/4 infectious events and there were 33 grade 5 pneumonias identified among the studies. A number of significant infectious events were attributed to atypical organisms such as Aspergillus spp., Cryptococcus neoformans and Pneumocystis jirovecii . Somewhat counterintuitively, the rates of all events (infections, pneumonia or any grade 5 event) were consistently lower in the studies involving combination regimens. This finding may represent a gap in the data as many of these trials are incomplete and many are only reported in abstract format at the time of this analysis. Alternatively, this may be due to a more heavily pretreated population with relatively diminished performance status enrolled in the single agent trials. Among all studies grade 3/4 pneumonia was seen in 13% of patients on ibrutinib alone and 7.8% of patients on combination therapy. Grade 5 infections accounted for 25-33% of all grade 5 events. With increasing use of targeted therapies in patients previously not eligible for standard cytotoxic regimens, clinicians must be aware of unanticipated side effects. In one trial with a high rate of invasive aspergillosis, there was no correlation between patient CD4+ T cell counts and rates of this opportunistic infection. A separate investigation identified high rates of P. jirovecii in patients on single agent ibrutinib. Inhibition of BTK in non-malignant monocytes has been a proposed mechanism of increased susceptibility to invasive fungal disease. Antimicrobial prophylaxis with ibrutinib use is not currently standard practice in the management of hematologic diseases. Our findings of high rates of infectious events, particularly pneumonia often related to opportunistic pathogens, suggest that vigilance for infection is mandatory, and that risk factors for predisposition to infection, beyond CD4+ T cell counts and immunoglobulin levels, should be sought. Download : Download high-res image (122KB) Download : Download full-size image Table . Disclosures Pauff: Abbvie: Employment." @default.
• W2785891500 created "2018-02-23" @default.
• W2785891500 creator A5007245891 @default.
• W2785891500 creator A5023992625 @default.
• W2785891500 creator A5044194506 @default.
• W2785891500 creator A5054836690 @default.
• W2785891500 creator A5056651290 @default.
• W2785891500 date "2017-12-07" @default.
• W2785891500 modified "2023-09-28" @default.
• W2785891500 title "Systematic Review of Infectious Events in Prospective Trials of Ibrutinib" @default.
• W2785891500 doi "https://doi.org/10.1182/blood.v130.suppl_1.3460.3460" @default.
• W2785891500 hasPublicationYear "2017" @default.
• W2785891500 type Work @default.
• W2785891500 sameAs 2785891500 @default.
• W2785891500 citedByCount "0" @default.
• W2785891500 crossrefType "journal-article" @default.
• W2785891500 hasAuthorship W2785891500A5007245891 @default.
• W2785891500 hasAuthorship W2785891500A5023992625 @default.
• W2785891500 hasAuthorship W2785891500A5044194506 @default.
• W2785891500 hasAuthorship W2785891500A5054836690 @default.
• W2785891500 hasAuthorship W2785891500A5056651290 @default.
• W2785891500 hasConcept C126322002 @default.
• W2785891500 hasConcept C143998085 @default.
• W2785891500 hasConcept C177713679 @default.
• W2785891500 hasConcept C197934379 @default.
• W2785891500 hasConcept C203014093 @default.
• W2785891500 hasConcept C2776694085 @default.
• W2785891500 hasConcept C2777063308 @default.
• W2785891500 hasConcept C2777525834 @default.
• W2785891500 hasConcept C2777714996 @default.
• W2785891500 hasConcept C2777938653 @default.
• W2785891500 hasConcept C2778461978 @default.
• W2785891500 hasConcept C2778570526 @default.
• W2785891500 hasConcept C2779338263 @default.
• W2785891500 hasConcept C2779524853 @default.
• W2785891500 hasConcept C2779878957 @default.
• W2785891500 hasConcept C2780653079 @default.
• W2785891500 hasConcept C2781442060 @default.
• W2785891500 hasConcept C535046627 @default.
• W2785891500 hasConcept C71924100 @default.
• W2785891500 hasConceptScore W2785891500C126322002 @default.
• W2785891500 hasConceptScore W2785891500C143998085 @default.
• W2785891500 hasConceptScore W2785891500C177713679 @default.
• W2785891500 hasConceptScore W2785891500C197934379 @default.
• W2785891500 hasConceptScore W2785891500C203014093 @default.
• W2785891500 hasConceptScore W2785891500C2776694085 @default.
• W2785891500 hasConceptScore W2785891500C2777063308 @default.
• W2785891500 hasConceptScore W2785891500C2777525834 @default.
• W2785891500 hasConceptScore W2785891500C2777714996 @default.
• W2785891500 hasConceptScore W2785891500C2777938653 @default.
• W2785891500 hasConceptScore W2785891500C2778461978 @default.
• W2785891500 hasConceptScore W2785891500C2778570526 @default.
• W2785891500 hasConceptScore W2785891500C2779338263 @default.
• W2785891500 hasConceptScore W2785891500C2779524853 @default.
• W2785891500 hasConceptScore W2785891500C2779878957 @default.
• W2785891500 hasConceptScore W2785891500C2780653079 @default.
• W2785891500 hasConceptScore W2785891500C2781442060 @default.
• W2785891500 hasConceptScore W2785891500C535046627 @default.
• W2785891500 hasConceptScore W2785891500C71924100 @default.
• W2785891500 hasLocation W27858915001 @default.
• W2785891500 hasOpenAccess W2785891500 @default.
• W2785891500 hasPrimaryLocation W27858915001 @default.
• W2785891500 hasRelatedWork W1778340936 @default.
• W2785891500 hasRelatedWork W1983784388 @default.
• W2785891500 hasRelatedWork W2036586160 @default.
• W2785891500 hasRelatedWork W2038558625 @default.
• W2785891500 hasRelatedWork W2047956359 @default.
• W2785891500 hasRelatedWork W2061556916 @default.
• W2785891500 hasRelatedWork W2261577429 @default.
• W2785891500 hasRelatedWork W2318735691 @default.
• W2785891500 hasRelatedWork W2319947595 @default.
• W2785891500 hasRelatedWork W2410021957 @default.
• W2785891500 hasRelatedWork W2412488579 @default.
• W2785891500 hasRelatedWork W2463699576 @default.
• W2785891500 hasRelatedWork W2602207034 @default.
• W2785891500 hasRelatedWork W2903883219 @default.
• W2785891500 hasRelatedWork W2905857557 @default.
• W2785891500 hasRelatedWork W2944844282 @default.
• W2785891500 hasRelatedWork W2977655178 @default.
• W2785891500 hasRelatedWork W2991178688 @default.
• W2785891500 hasRelatedWork W3015744343 @default.
• W2785891500 hasRelatedWork W3201123776 @default.
• W2785891500 hasVolume "130" @default.
• W2785891500 isParatext "false" @default.
• W2785891500 isRetracted "false" @default.
• W2785891500 magId "2785891500" @default.
• W2785891500 workType "article" @default.